{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.8","upperLimit":"70.1","value":"43.8"},{"groupId":"OG001","lowerLimit":"43.5","upperLimit":"62.4","value":"53.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"ORR, which includes complete response (CR) and partial response (PR) in the Main cohort as determined by IRC assessment. ORR is the percentage of participants with a best overall disease response of CR or PR, where the best overall disease response is defined as the best disease response recorded from CTL019 infusion until progressive disease or start of new anticancer therapy (including ASCT), whichever comes first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG000","title":"Tisagenlecleucel - Cohort A"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US and at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG001","title":"Tisagenlecleucel - All Patients"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Overall Response Rate (ORR) Per Independent Review Committee (IRC) in Cohort A & in All Patients","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}